Trichoepithelioma is a rare type of benign tumor that is an adnexal tumor of the skin and derived from the hair follicle epithelium. Protheragen offers a wide variety of Trichoepithelioma diagnostic and therapeutic drug development services, which include biomarker development, drug discovery, and preclinical studies.
Overview of Trichoepithelioma
Trichoepithelioma is an uncommon benign tumor of skin appendages that arises from the hair follicles. Its features include the formation of numerous skin colored, pink, or even bluish papules or nodules, most commonly located on the face, especially on and around the nasolabial folds, the nose, forehead, and eyelids. The condition usually starts in early childhood or in the teenage years, and there is an increase in size and number with time. While usually painless, trichoepithelioma is cosmetically disfiguring, which can cause psychosocial morbidity. The condition can occasionally transform malignant into basal cell carcinoma or trichoblastic carcinoma.
Fig.1 A well-circumscribed dermal tumor with epithelial and stromal components. (Lobo Y.,
et al., 2021)
Pathogenesis of Trichoepithelioma
Trichoepithelioma is associated with two primary genetic mutations:
- Chromosome 9p21 Mutation: This mutation was the first to be identified and is linked to multiple familial trichoepithelioma (MFT).
- CYLD Gene Mutation (Chromosome 16q12-q13): This mutation encodes a deubiquitinating enzyme that negatively regulates the activation of nuclear factor kappa B (NF-κB) and c-Jun N-terminal kinase pathways. Dysregulation of these pathways leads to abnormal proliferation and differentiation of the pilosebaceous-apocrine unit. The CYLD gene mutation is also implicated in Brooke-Spiegler syndrome, an inherited disorder characterized by multiple adnexal tumors such as trichoepitheliomas, cylindromas, and spiradenomas.
Diagnostics Development for Trichoepithelioma
Histopathological Diagnostics
Histological examination remains the gold standard for diagnosing trichoepithelioma. The lesions are characterized by the presence of horn cysts and tumor islands made up of basaloid cells. These tumors often present with palisading at the periphery of the islands, surrounded by a dense fibrous stroma. The key histopathological feature differentiating trichoepithelioma from other cutaneous neoplasms like basal cell carcinoma (BCC) is the presence of well-formed cornified cysts and papillary mesenchymal bodies within the tumor islands.
Molecular Diagnostics
Recent advances in genetic diagnostics have enabled the identification of specific mutations in the CYLD and 9p21 genes associated with multiple familial trichoepitheliomas. Genetic testing, including next-generation sequencing (NGS), has proven effective in diagnosing familial cases and distinguishing them from sporadic lesions. In some instances, whole exome sequencing (WES) can identify additional genetic aberrations that contribute to disease progression.
Immunohistochemistry (IHC)
Immunohistochemical staining is increasingly being used to differentiate trichoepithelioma from other cutaneous tumors. CD34, bcl-2, and p75 neurotrophin receptor (p75NTR) have shown promise as potential biomarkers to distinguish between trichoepitheliomas and basal cell carcinomas (BCC), especially in small skin biopsies. These markers are useful when histological features alone are not definitive, offering a complementary diagnostic approach.
Therapeutics of Trichoepithelioma
| Therapeutics |
Drug Name |
Mechanism |
Description |
Stage |
| Topical Therapy |
Sirolimus (Rapamycin) |
mTOR Inhibitor |
Applied topically to reduce the density of trichoepitheliomas and prevent new lesions. |
Approved |
| Topical Therapy |
Imiquimod |
Immunomodulator |
Stimulates the secretion of TNF-α and IFN-γ, promoting a Th1 lymphocyte-mediated immune response. |
Approved |
| Topical Therapy |
Tretinoin |
Retinoid |
Normalizes epidermal turnover and flattens trichoepitheliomas, enhancing the absorption of other topical agents. |
Approved |
| Systemic Therapy |
Aspirin |
Anti-inflammatory |
Inhibits NF-κB activation, reducing inflammation and proliferation of trichoepitheliomas. |
Approved |
| Systemic Therapy |
Adalimumab |
TNF-α Inhibitor |
Neutralizes TNF-α, reducing inflammation and proliferation of trichoepitheliomas. |
Approved |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
At Protheragen, we provide a wide range of services to support the development of diagnostics and therapeutics for trichoepithelioma. Our offerings include histopathological examination, immunohistochemical staining, genetic testing, and the development and evaluation of novel pharmacological agents.
Disease Models
- CYLD Mutant Mice
- β-Catenin Overexpression Mice
- Chemically Induced Skin Tumor Models in Mice or Rats.
- UV-induced Skin Tumor Models in Mice
Protheragen specializes in preclinical research, offering in vitro and in vivo studies, pharmacokinetics and pharmacodynamics analysis, and efficacy and safety evaluations. Our customized services are designed to meet the unique needs of each client, ensuring that we provide tailored solutions to address specific challenges and goals. If you are interested in our services, please feel free to
contact us.
References
- Lobo, Yolanka, Tristan Blake, and Laura Wheller. "Management of multiple trichoepithelioma: A review of pharmacological therapies." Australasian Journal of Dermatology 62.2 (2021): e192-e200.
- Karimzadeh, Iman, Mohammad Reza Namazi, and Amin Karimzadeh. "Trichoepithelioma: a comprehensive review." Acta Dermatovenerologica Croatica 26.2 (2018): 162-162.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
